US EditionA short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
- A Nature Medicine paper published on Monday by Erritzoe and colleagues reported that a single intravenous DMT dose rapidly reduced depressive symptoms in 34 adults with major depressive disorder.
- Many people with major depressive disorder do not respond adequately to selective serotonin reuptake inhibitors or tolerate side effects, while dimethyltryptamine's brief intravenous effects could enable shorter therapy sessions.
- The randomized design assigned 17 people to each arm, administering intravenous infusions over about 10 minutes, and by two weeks DMT recipients showed greater depression score reductions with 47% meeting remission by three months.
- In terms of safety, researchers reported side-effect rates of 64.7% and 62.5% with DMT versus 23.5% placebo, noting study limitations including small sample and 88.2% white participants.
- Regulatory reviews and larger phase 3 trials will determine clinical adoption, with Erritzoe's team testing HLP004 and others like AtaiBeckley and 5‑MeO‑DMT advancing in parallel.
22 Articles
22 Articles
Major depressive disorder is one of the leading causes of disability worldwide
Major depression is one of the main causes of disability in the world and, despite advances in psychopharmaceuticals and psychotherapy, a significant part of patients do not respond to conventional treatments.In this context, the search for innovative alternatives has led to research on psychedelic substances, such as dimethyltryptamine (DMT), present in ayahuasca, a traditional Amazonian drink.A clinical trial, published this week in the presti…
Preliminary, the results add to a growing body of evidence that psychedelic drugs, when combined with psychotherapy, can help alleviate depression in millions of people worldwide.
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and s
A single dose of dimethyltryptamine - active substance of ayahuasca - and administered with psychological support quickly reduced depressive symptoms.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
